Patent: 10,227,400
✉ Email this page to a colleague
Summary for Patent: 10,227,400
Title: | Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies |
Abstract: | The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human. |
Inventor(s): | Andrien, Jr.; Bruce A. (Guilford, CT), Sheridan; Douglas L. (Branford, CT), Tamburini; Paul P. (Kensington, CT), Wang; Yi (Woodbridge, CT) |
Assignee: | Alexion Pharmaceuticals, Inc. (Boston, MA) |
Application Number: | 15/708,658 |
Patent Claims: | see list of patent claims |
Details for Patent 10,227,400
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Alexion Pharmaceuticals, Inc. | ULTOMIRIS | ravulizumab-cwvz | Injection | 761108 | 12/21/2018 | ⤷ Try a Trial | 2034-03-07 |
Alexion Pharmaceuticals, Inc. | ULTOMIRIS | ravulizumab-cwvz | Injection | 761108 | 10/09/2020 | ⤷ Try a Trial | 2034-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,227,400
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2015134894 | ⤷ Try a Trial |
United States of America | 9803007 | ⤷ Try a Trial |
United States of America | 9663574 | ⤷ Try a Trial |
United States of America | 9371377 | ⤷ Try a Trial |
United States of America | 9206251 | ⤷ Try a Trial |
United States of America | 9107861 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |